{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T02:38:46Z","timestamp":1771900726887,"version":"3.50.1"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T00:00:00Z","timestamp":1640649600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Concerns exist regarding the risk of infections in patients with spondyloarthritis (SpA) treated with biologics. We assessed the risk of infections of biological and targeted drugs in patients with SpA by performing a meta-analysis based on randomized controlled trials (RCTs).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A systematic literature search was conducted in PubMed, Embase, Web of Science, the Cochrane Library, and China Biology Medicine Disc for RCTs evaluating the risk of infections of biological therapy in patients with SpA from inception through August 9, 2021. We calculated a pooled Peto odds ratio (OR) for infections in biologics-treated patients <jats:italic toggle=\"yes\">vs.<\/jats:italic> placebo patients. The risk of bias on the included RCTs was assessed by using the Cochrane Risk of Bias Tool.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>In total, 62 studies were included in this meta-analysis. Overall, the risk of infection (Peto OR: 1.16, 95% confidence interval [CI]: 1.07\u20131.26, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a0.001), serious infection (Peto OR: 1.65, 95% CI: 1.26\u20132.17, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a0.001), upper respiratory tract infection (URTI) (Peto OR: 1.17, 95% CI: 1.04\u20131.32, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a0.008), nasopharyngitis (Peto OR: 1.25, 95% CI: 1.10\u20131.42, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a0.001), and <jats:italic toggle=\"yes\">Candida<\/jats:italic> infection (Peto OR: 2.64, 95% CI: 1.48\u20134.71, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a\n                                 <jats:italic toggle=\"yes\">=<\/jats:italic>\u200a0.001) were increased in SpA patients treated with biologics compared with placebo. Sensitivity analysis based on biologics classes was conducted, and results demonstrated that compared with placebo, there was a higher risk of infection for tumor necrosis factor (TNF)-a inhibitors (Peto OR: 1.38, 95% CI: 1.13\u20131.68, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a\n                                 <jats:italic toggle=\"yes\">=<\/jats:italic>\u200a0.001) and interleukin (IL)-17 inhibitors (Peto OR: 1.55, 95% CI: 1.08\u20132.22, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a\n                                 <jats:italic toggle=\"yes\">=<\/jats:italic>\u200a0.018) in axial SpA, and for Janus kinase inhibitors in peripheral SpA (Peto OR: 1.39, 95% CI: 1.14\u20131.69, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a\n                                 <jats:italic toggle=\"yes\">=<\/jats:italic>\u200a0.001); higher risk of serious infection for IL-17 inhibitors in peripheral SpA (Peto OR: 3.46, 95% CI: 1.26\u20139.55, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a0.016) and axial SpA (Peto OR: 2.01, 95% CI: 1.38\u20132.91, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a0.001); higher risk of URTI for TNF-a inhibitors in axial SpA (Peto OR: 1.37, 95% CI: 1.05\u20131.78, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a0.019), and for apremilast in peripheral SpA (Peto OR: 1.60, 95% CI: 1.08\u20132.36, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a0.018); higher risk of nasopharyngitis for TNF-a inhibitors in axial SpA (Peto OR: 1.41, 95% CI: 1.05\u20131.90, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a0.022) and peripheral SpA (Peto OR: 1.49, 95% CI: 1.09\u20132.05, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a0.013), and for IL-17 inhibitors in axial SpA (Peto OR: 1.35, 95% CI: 1.01\u20131.82, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a0.044); higher risk of herpes zoster for Janus kinase inhibitors in peripheral SpA (Peto OR: 2.18, 95% CI: 1.03\u20134.62, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a0.043); higher risk of <jats:italic toggle=\"yes\">Candida<\/jats:italic> infection for IL-17 inhibitors in peripheral SpA (Peto OR: 2.52, 95% CI: 1.31\u20134.84, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a0.006).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This meta-analysis shows that biological therapy in patients with SpA may increase the risk of infections, including serious infections, URTI, nasopharyngitis, and <jats:italic toggle=\"yes\">Candida<\/jats:italic> infection, which should be paid attention to in our clinical practice.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cm9.0000000000001928","type":"journal-article","created":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T09:02:04Z","timestamp":1640854924000},"page":"911-919","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Risk of infections of biological and targeted drugs in patients with spondyloarthritis: meta-analysis of randomized clinical trials"],"prefix":"10.1097","volume":"135","author":[{"given":"Lidong","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, The First Medical Center, Chinese PLA General Hospital, Beijing 100853, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siliang","family":"Man","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Beijing Jishuitan Hospital, Beijing 100035, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojian","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The First Medical Center, Chinese PLA General Hospital, Beijing 100853, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiwen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The First Medical Center, Chinese PLA General Hospital, Beijing 100853, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingkang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The First Medical Center, Chinese PLA General Hospital, Beijing 100853, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaxin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The First Medical Center, Chinese PLA General Hospital, Beijing 100853, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuan","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The First Medical Center, Chinese PLA General Hospital, Beijing 100853, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The First Medical Center, Chinese PLA General Hospital, Beijing 100853, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The First Medical Center, Chinese PLA General Hospital, Beijing 100853, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,4,20]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ijosm.2021.03.005","article-title":"Masterclass: axial spondyloarthritis for osteopaths and manual therapists","volume":"41","author":"MacMillan","year":"2021","journal-title":"Int J Osteopath Med"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1097\/CM9.0000000000001099","article-title":"Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52 week, phase III China-centric study, MEASURE 5","volume":"133","author":"Huang","year":"2020","journal-title":"Chin Med J"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1097\/CM9.0000000000000711","article-title":"A novel treatment for psoriatic arthritis: Janus kinase inhibitors","volume":"133","author":"Chen","year":"2020","journal-title":"Chin Med J"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"618581","DOI":"10.3389\/fimmu.2021.618581","article-title":"The role of the IL-23\/IL-17 axis in disease initiation in spondyloarthritis: lessons learned from animal models","volume":"12","author":"Mandour","year":"2021","journal-title":"Front Immunol"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"596086","DOI":"10.3389\/fimmu.2020.596086","article-title":"The IL-17\/IL-23 axis and its genetic contribution to psoriatic arthritis","volume":"11","author":"Vecellio","year":"2020","journal-title":"Front Immunol"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"674","DOI":"10.21037\/atm-19-1739","article-title":"The activation of IL-17 signaling pathway promotes pyroptosis in pneumonia-induced sepsis","volume":"8","author":"Li","year":"2020","journal-title":"Ann Transl Med"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1084\/jem.20050193","article-title":"Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniae","volume":"202","author":"Happel","year":"2005","journal-title":"J Exp Med"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nm1710","article-title":"IL- 22 mediates mucosal host defense against Gram-negative bacterial pneumonia","volume":"14","author":"Aujla","year":"2008","journal-title":"Nat Med"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.4049\/jimmunol.0803075","article-title":"A MyD88-dependent early IL-17 production protects mice against airway infection with the obligate intracellular pathogen Chlamydia muridarum","volume":"183","author":"Zhang","year":"2009","journal-title":"J Immunol"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.immuni.2009.08.025","article-title":"Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis","volume":"31","author":"Lin","year":"2009","journal-title":"Immunity"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1084\/jem.20081463","article-title":"Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis","volume":"206","author":"Conti","year":"2009","journal-title":"J Exp Med"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1038\/jid.2008.139","article-title":"Patients with chronic mucocutaneous candidiasis exhibit reduced production of Th17-associated cytokines IL-17 and IL-22","volume":"128","author":"Eyerich","year":"2008","journal-title":"J Invest Dermatol"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1002\/acr.24025","article-title":"2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1136\/ard.2008.098822","article-title":"Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta analysis of randomised placebo-controlled trials","volume":"69","author":"Fouque-Aubert","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s10067-017-3966-1","article-title":"Risk of serious infections in biological treatment of patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis","volume":"37","author":"Wang","year":"2017","journal-title":"Clin Rheumatol"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","article-title":"Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta analysis","volume":"158","author":"Olivera","year":"2020","journal-title":"Gastroenterology"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"e001395","DOI":"10.1136\/rmdopen-2020-001395","article-title":"Long-term safety of tofacitinib up to 9.5\u200ayears: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme","volume":"6","author":"Cohen","year":"2020","journal-title":"RMD Open"},{"issue":"(Suppl 2)","key":"R21-20250603","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/annrheumdis-2019-eular.621","article-title":"OP0028 post-approval comparative safety study of tofacitinib and biologic DMARDs: five-year results from a US-based rheumatoid arthritis registry","volume":"78","author":"Kremer","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.mayocp.2020.01.039","article-title":"Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: a systematic review and meta-analysis","volume":"95","author":"Wang","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1136\/annrheumdis-2015-eular.3674","article-title":"THU0178 relationship between NK cell count and important safety events in rheumatoid arthritis patients treated with tofacitinib","volume":"74","author":"van Vollenhoven","year":"2015","journal-title":"Ann Rheum Dis"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000001928","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T19:00:58Z","timestamp":1748977258000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000001928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,28]]},"references-count":23,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000001928","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,28]]}}}